Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer

Research output: Contribution to journalArticle

Abstract

Aim: To evaluate the role of pegylated liposomal doxorubicin with low-dose metronomic cyclophosphamide as primary systemic treatment in locally advanced breast cancer. Patients and Methods: The activity and safety of intravenous pegylated liposomal doxorubicin 20 mg sqm -1 biweekly for eight courses in combination with metronomic cyclophosphamide 50 mg day -1 orally were evaluated in 29 patients with locally advanced breast cancer who were not suitable to receive a standard chemotherapy due to age or co-morbidities or who asked for a regimen with low incidence of toxic effects irrespective of age. Results: The rate of breast-conserving surgery was 44.8%. Eighteen patients (62.1%) achieved a partial response (including one pathological complete response), 10 (34.5%) a stable disease and one patient experienced a progressive disease. Treatment was well tolerated, with no grade 4 toxicities, and with grade 3 skin toxicity in three patients and hand-foot syndrome in four patients. Conclusion: The regimen was well tolerated but with limited activity in the preoperative setting. Other options (e.g., endocrine therapy in estrogen receptor -positive disease) should be considered in locally advanced breast cancer patients who are not suitable to receive a standard chemotherapy.

Original languageEnglish
Pages (from-to)319-323
Number of pages5
JournalBreast
Volume20
Issue number4
DOIs
Publication statusPublished - Aug 2011

Keywords

  • Breast cancer
  • Chemotherapy
  • Elderly
  • Locally advanced
  • Metronomic cyclophosphamide
  • Pegylated liposomal doxorubicin

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer'. Together they form a unique fingerprint.

  • Cite this